Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kreitman, R. R.
Right arrow Articles by Blanchette, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kreitman, R. R.
Right arrow Articles by Blanchette, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 10, No. 3 suppl, S81-S89 (2004)
DOI: 10.1191/1352458504ms1037oa
© 2004 SAGE Publications

On the horizon: possible neuroprotective role for glatiramer acetate

Rivka Riven Kreitman

Teva Neuroscience, North Wales, PA, USA, rivka.kreitman{at}tevaneuro.com

François Blanchette

Teva Neuroscience, Montréal, Québec, Canada

Inflammation and neurodegeneration characterize the pathogenesis of multiple sclerosis (MS). Slow axonal degeneration, rather than acute inflammation, is considered the cause of chronic disability in MS. The signs of acute axonal damage and loss have been shown to occur early in the lesion development of patients with chronic MS and often correlate with demyelination and inflammation. While immune activity in the central nervous system has traditionally been considered to be a detrimental event in MS, recent studies have found that autoimmune T cells may play an important role in protecting neurons from the ongoing spreading damage. Neuroprotectio n in MS is a new and evolving concept, and many questions remain with regard to potential targets for therapeutic intervention. Preliminary studies, both in animals and in humans, have suggested that glatiramer acetate (GA) may confer neuroprotective activity in addition to bystander suppression. Additional research is needed to determine if these promising neuroprotective effects correlate with the long-term effect of G A in MS.

Key Words: BDNF • black holes • Copaxone • EA E • glatiramer acetate • MRI • multiple sclerosis • neuroprotection • neurotropic factors • protective autoimmunity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
K. Hamamcioglu and A. Reder
Interferon-{beta} regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis
Multiple Sclerosis, May 1, 2007; 13(4): 459 - 470.
[Abstract] [PDF]